Angiotensin converting enzyme II (ACE2), the newest identified member of renin‐angiotensin system (RAS), catalyses the conversion of angiotensin (ang)‐II to ang‐(1‐7) which plays a compensatory role through Mas1 receptor in the cardiovascular system. We previously reported that decreased ACE2 expression and activity leads to the development of ang‐II‐mediated hypertension in mice, that ang‐II stimulated ACE2 internalization and degradation in lysosomes and that inhibition of this process prevents the hypertensive actions of ang‐II. On the other hand, severe acute respiratory syndrome coronavirus is internalized together with ACE2, clearly indicating a regulated endocytotic mechanisms for this enzyme. However, the molecular mechanisms controlling this event remain largely unknown and the aim of the present study was to clarify these aspects.We first performed a proteomic study in HEK293T cells co‐transfected with ACE2 and AT1R and found that ang‐II treatment (100 nM, 4 h) significantly changed the interactions of ACE2 only with fascin, an actin‐bundling protein. Confocal microscopy experiments confirmed that ang‐II strongly enhanced the co‐localization of the two proteins in the perinuclear space. In addition, we demonstrated that ang‐II treatment augmented ubiquitination of ACE2 and amino acid analysis indicated that in the C‐terminus the enzyme has only five putative lysine ubiquitination sites. Six ACE2 mutants were constructed, five in which each individual ubiquitination site was replaced by arginine, and the sixth mutant (ACE2‐L5R) included all five mutations. In basal conditions in HEK293T cells co‐transfected with AT1R, ACE2 wild‐type activity was 3536.88 ±331.63FU/min/μg protein. Ang‐II treatment (100 nM, 4h) significantly attenuated enzymatic activity (3298.60±255.89). Remarkably, every mutant displayed enhanced enzymatic activity in basal conditions of at least 195±45%, with the highest increase observed in the case of ACE2‐L5R mutant being 285±61%. Furthermore, none of these ACE2 mutants displayed decreased enzymatic activity after ang‐II treatment. The present results demonstrate that ACE2 is constitutively ubiquinated and that this posttranslational modification is augmented by increased levels of ang‐II, contributing to lysosomal degradation of the enzyme in fascin‐dependent manner and overall diminishing its compensatory role against overactive RAS. These data indicate that interfering with the mechanisms contributing to ang‐II‐mediated ACE2 degradation may constitute an alternative therapy in cardiovascular diseases.Support or Funding InformationSupported by NIH‐P20‐GM103514 (EL, JJG and CMF), R01‐HL093178 (EL), and startup funds from Howard University (CMF)
Read full abstract